SlideShare una empresa de Scribd logo
1 de 11
Niemann-Pick Disease
Maggie W. George
December 5, 2005
The Disease
 Condition involving the breakdown and use of fats and
cholesterol in the body
 Harmful amounts of lipids accumulate in the spleen, liver,
lungs, bone marrow, and brain
 Autosomal recessive pattern of inheritance (two copies of the
gene must be present)
 Four variants: A, B, C1, and C2
 Clinical feature include: severe liver disease, breathing
difficulties, developmental delay, seizures, increased muscle
tone, lack of coordination, problems feeding, and inability to
move eyes vertically.
 No treatment
Variants
 Types A and B: mutated SMPD1 gene
 SMPD gene carries instructions for cells to produce,
sphingomyelinase, which processes lipids.
 Mutations lead to deficiency of sphingomyelinase and
accumulations of cholesterol and lipids.
 Types C1 and C2: mutated NCP1 or NCP2 gene
 NCP1 gene produces a protein involved in the movement of
cholesterol and lipids within a cell.
 May be a cholesterol pump, which is why its mutation leads
to the buildup of lipids and cholesterol in the cell membrane.
 Plays a critical role in regulation of intracellular cholesterol
trafficking
 NCP2 gene produces protein that binds and transports
cholesterol (not fully understood).
NCP1 v. NCP2 Gene
 95% of patients have mutations in the NPC1 gene
 Mapped at chromosome 18q11
 NPC1 encodes a 1278 amino acid glycoprotein with 13
transmembrane domains.
 Remainder of patients have mutations in the NPC2 gene (or
HE1 gene)
 Mapped at chromosome 14q24.3
 Encodes a small soluble lysosomal protein involved in
cholesterol binding.
 Both genes have identical biochemical patterns suggesting that
the two proteins function together in cellular transport of
cholesterol, glycolipids, etc.
 Work together to facilitate the intracellular transport of lipids
from the lysosome to other cellular sites.
 Their precise functions and relationship remain unclear and are
currently the subject of intense investigation.
NCP1 Mutations
 Over 130 mutations have been identified in NPC1
 Results in Niemann-Pick Disease Type C1
 Most found within a NPC1 specific cysteine-rich domain, suggesting that the
integrity of this region is crucial for normal functioning of the protein.
 Mutations include: missense mutations, small deletions that generate
premature stop codons, intronic mutations predicted to alter splicing, and
point mutations.
Specific mutation examples:
 exon 20 c.2932 C>T
 c.882-28 A>G (note that patients with this mutation had fibroblasts
containing small amounts of mRNA without exon 7)
 point mutation in exon 20 (causing frameshift and premature stop codon)
 1553G-A transition (causing a splicing error of exon 9)
 2783A-C transversion that results in a gln928-to-pro amino acid
substitution
 3263A-G transition leading to a tyr1088-to-cys amino acid substitution
 530G-A change in exon 5, resulting in a cys177-to-tyr substitution
 4-bp deletion, TTAC
NCP2 Mutations
 Results in Niemann-Pick Disease Type C2 and frontal lobe atrophy
 Single amino acid changes prevents both cholesterol binding and the restoration of
normal cholesterol levels in mutant cells.
Specific mutation examples: 16 mutant alleles were identified representing only 5 different
mutations (all had a severe impact on the protein):
1. 2 nonsense mutations, glu20 to ter (E20X): associated with severe rapid disease course
• Results in a frameshift in exon 2, which generates a stop codon 4 codons downstream of
frameshift
• Lung involvement  death from respiratory failure
1. Glu118 to ter substitution (E118X)
• Result of a G-to-T transversion at nucleotide 352 in exon 1 of HE1 gene
1. 1-bp deletion (27delG)
2. Splice mutation (IVS2+5G-A): very difference clinical presentation
• Milder phenotype
• Childhood onset of neurologic symptoms but prolonged survival
1. Missense mutation (S67P)  resulting in reduced amts of abnormal HE1 protein.
*E20X was established as the most common mutant allele (56% frequency)
Lack of Knowledge
 Unfortunately, the NCP1 and the NCP2
gene are not fully understood, which means
there is no proposed structure for either.
 There is a structure for the NCP2 bovine
gene, but then again there is little
information about the actual mutations
involved.
Human to Bovine Relationship
References
 http://en.wikipedia.org/wiki/Niemann-Pick_disease
 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search
 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
db=PubMed&cmd=Retrieve&list_uids=12401890
 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
db=PubMed&cmd=Retrieve&list_uids=15774455
 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_u
ids=12974729&query_hl=1&itool=pubmed_docsum

Más contenido relacionado

La actualidad más candente (20)

Inborn errors of metabolism
Inborn errors of metabolismInborn errors of metabolism
Inborn errors of metabolism
 
Niemann Pick Disease
Niemann Pick DiseaseNiemann Pick Disease
Niemann Pick Disease
 
lipid storage diseases
lipid storage diseaseslipid storage diseases
lipid storage diseases
 
Mucopolysaccharidosis
MucopolysaccharidosisMucopolysaccharidosis
Mucopolysaccharidosis
 
GLCOGEN STORAGE DISORDERS
GLCOGEN STORAGE DISORDERSGLCOGEN STORAGE DISORDERS
GLCOGEN STORAGE DISORDERS
 
Lysosomal Storage Disease
Lysosomal Storage DiseaseLysosomal Storage Disease
Lysosomal Storage Disease
 
Mitochondrial diseases
Mitochondrial diseasesMitochondrial diseases
Mitochondrial diseases
 
Sphingolipidoses
Sphingolipidoses Sphingolipidoses
Sphingolipidoses
 
Tay – sachs disease
Tay – sachs diseaseTay – sachs disease
Tay – sachs disease
 
Mitochondrial encephalomyopathies(Neurology)
Mitochondrial encephalomyopathies(Neurology)Mitochondrial encephalomyopathies(Neurology)
Mitochondrial encephalomyopathies(Neurology)
 
Lysosomal storage diseases
Lysosomal storage   diseasesLysosomal storage   diseases
Lysosomal storage diseases
 
dr Mahtab
 dr Mahtab dr Mahtab
dr Mahtab
 
The biochemistry of tay sachs disease
The biochemistry of tay sachs disease The biochemistry of tay sachs disease
The biochemistry of tay sachs disease
 
Glycogen storage disease (gsd)
Glycogen                  storage                    disease (gsd)Glycogen                  storage                    disease (gsd)
Glycogen storage disease (gsd)
 
LIPID STORAGE DISEASES
LIPID STORAGE DISEASESLIPID STORAGE DISEASES
LIPID STORAGE DISEASES
 
gaucher disease Presentation1
gaucher disease Presentation1gaucher disease Presentation1
gaucher disease Presentation1
 
Lipid storage diseases
Lipid storage diseasesLipid storage diseases
Lipid storage diseases
 
Gaucher Disease
Gaucher DiseaseGaucher Disease
Gaucher Disease
 
Lesch–nyhan syndrome
Lesch–nyhan syndromeLesch–nyhan syndrome
Lesch–nyhan syndrome
 
Homocystinuria
HomocystinuriaHomocystinuria
Homocystinuria
 

Similar a Niemann pick disease

Infect. Immun.-2016-Jain-439-51
Infect. Immun.-2016-Jain-439-51Infect. Immun.-2016-Jain-439-51
Infect. Immun.-2016-Jain-439-51Neena Jain
 
Brenna O-GlcNAc Final Poster
Brenna O-GlcNAc Final Poster Brenna O-GlcNAc Final Poster
Brenna O-GlcNAc Final Poster Brenna Seawalt
 
AICHE Regional Conference Poster
AICHE Regional Conference PosterAICHE Regional Conference Poster
AICHE Regional Conference PosterAnastasia Neuman
 
Beta cell failure, stress and dm2
Beta cell failure, stress and dm2Beta cell failure, stress and dm2
Beta cell failure, stress and dm2Ruy Pantoja
 
Pharmacogenomics implication of risk SNPs in diabetes
Pharmacogenomics implication of risk SNPs in diabetesPharmacogenomics implication of risk SNPs in diabetes
Pharmacogenomics implication of risk SNPs in diabetesMuhammad Huzaimi Haron
 
Erstressindiabeticcomplicationfinal 150505043746-conversion-gate02 (2)
Erstressindiabeticcomplicationfinal 150505043746-conversion-gate02 (2)Erstressindiabeticcomplicationfinal 150505043746-conversion-gate02 (2)
Erstressindiabeticcomplicationfinal 150505043746-conversion-gate02 (2)Basveshwar Gawali
 
ENDOPLASMIC RETICULUM STRESS IN DIABETIC COMPLICATIONS
ENDOPLASMIC RETICULUM STRESS IN DIABETIC COMPLICATIONSENDOPLASMIC RETICULUM STRESS IN DIABETIC COMPLICATIONS
ENDOPLASMIC RETICULUM STRESS IN DIABETIC COMPLICATIONSBasweshwar Gawali
 
Molecular Genetics in MPN
Molecular Genetics in MPNMolecular Genetics in MPN
Molecular Genetics in MPNARUN KUMAR
 
Neurological disorders arising from gene expression defects
Neurological disorders arising from gene expression defectsNeurological disorders arising from gene expression defects
Neurological disorders arising from gene expression defectsDenise Sheer
 
Mitochondrial disorders
Mitochondrial disordersMitochondrial disorders
Mitochondrial disordersAmr Saeed
 
Presentation on Gene Therapy for Cardiovascular Diseases.pptx
Presentation on Gene Therapy for Cardiovascular Diseases.pptxPresentation on Gene Therapy for Cardiovascular Diseases.pptx
Presentation on Gene Therapy for Cardiovascular Diseases.pptxJahangirnagar University
 
Path physiology of sepsis. SIRS & MOF
Path physiology of sepsis. SIRS & MOFPath physiology of sepsis. SIRS & MOF
Path physiology of sepsis. SIRS & MOFEneutron
 
Genetics of Mitochondrial disorders
Genetics of Mitochondrial disordersGenetics of Mitochondrial disorders
Genetics of Mitochondrial disordersPramod Krishnan
 
check point in cell cycle and the Mutation
  check point in  cell cycle and the Mutation   check point in  cell cycle and the Mutation
check point in cell cycle and the Mutation MustafaKareem19
 

Similar a Niemann pick disease (20)

Infect. Immun.-2016-Jain-439-51
Infect. Immun.-2016-Jain-439-51Infect. Immun.-2016-Jain-439-51
Infect. Immun.-2016-Jain-439-51
 
Brenna O-GlcNAc Final Poster
Brenna O-GlcNAc Final Poster Brenna O-GlcNAc Final Poster
Brenna O-GlcNAc Final Poster
 
Epigenetics and type 2 diabetes
Epigenetics and type 2 diabetesEpigenetics and type 2 diabetes
Epigenetics and type 2 diabetes
 
AICHE Regional Conference Poster
AICHE Regional Conference PosterAICHE Regional Conference Poster
AICHE Regional Conference Poster
 
Diabetic nephropathy
Diabetic nephropathyDiabetic nephropathy
Diabetic nephropathy
 
Beta cell failure, stress and dm2
Beta cell failure, stress and dm2Beta cell failure, stress and dm2
Beta cell failure, stress and dm2
 
Pharmacogenomics implication of risk SNPs in diabetes
Pharmacogenomics implication of risk SNPs in diabetesPharmacogenomics implication of risk SNPs in diabetes
Pharmacogenomics implication of risk SNPs in diabetes
 
Erstressindiabeticcomplicationfinal 150505043746-conversion-gate02 (2)
Erstressindiabeticcomplicationfinal 150505043746-conversion-gate02 (2)Erstressindiabeticcomplicationfinal 150505043746-conversion-gate02 (2)
Erstressindiabeticcomplicationfinal 150505043746-conversion-gate02 (2)
 
ENDOPLASMIC RETICULUM STRESS IN DIABETIC COMPLICATIONS
ENDOPLASMIC RETICULUM STRESS IN DIABETIC COMPLICATIONSENDOPLASMIC RETICULUM STRESS IN DIABETIC COMPLICATIONS
ENDOPLASMIC RETICULUM STRESS IN DIABETIC COMPLICATIONS
 
Molecular Genetics in MPN
Molecular Genetics in MPNMolecular Genetics in MPN
Molecular Genetics in MPN
 
Neurological disorders arising from gene expression defects
Neurological disorders arising from gene expression defectsNeurological disorders arising from gene expression defects
Neurological disorders arising from gene expression defects
 
Mitochondrial disorders
Mitochondrial disordersMitochondrial disorders
Mitochondrial disorders
 
Presentation on Gene Therapy for Cardiovascular Diseases.pptx
Presentation on Gene Therapy for Cardiovascular Diseases.pptxPresentation on Gene Therapy for Cardiovascular Diseases.pptx
Presentation on Gene Therapy for Cardiovascular Diseases.pptx
 
Path physiology of sepsis. SIRS & MOF
Path physiology of sepsis. SIRS & MOFPath physiology of sepsis. SIRS & MOF
Path physiology of sepsis. SIRS & MOF
 
Genetics of Mitochondrial disorders
Genetics of Mitochondrial disordersGenetics of Mitochondrial disorders
Genetics of Mitochondrial disorders
 
Mieloproliferativo
MieloproliferativoMieloproliferativo
Mieloproliferativo
 
check point in cell cycle and the Mutation
  check point in  cell cycle and the Mutation   check point in  cell cycle and the Mutation
check point in cell cycle and the Mutation
 
Cell cycle regulation
Cell cycle regulationCell cycle regulation
Cell cycle regulation
 
Cell cycle regulation
Cell cycle regulationCell cycle regulation
Cell cycle regulation
 
Cell cycle regulation
Cell cycle regulationCell cycle regulation
Cell cycle regulation
 

Más de Dr Ramesh Krishnan (20)

Diagnosis and management of Hyperkalemia
 Diagnosis and management of Hyperkalemia Diagnosis and management of Hyperkalemia
Diagnosis and management of Hyperkalemia
 
Abg ramesh
Abg rameshAbg ramesh
Abg ramesh
 
Ischemic heart disease
Ischemic heart disease Ischemic heart disease
Ischemic heart disease
 
Approach to management of Hyperkalemia
Approach to management of  HyperkalemiaApproach to management of  Hyperkalemia
Approach to management of Hyperkalemia
 
Anemia in ckd
Anemia in ckd Anemia in ckd
Anemia in ckd
 
Uti
UtiUti
Uti
 
Chronopharmacology
ChronopharmacologyChronopharmacology
Chronopharmacology
 
Betaadrenergicblockers 150412052808-conversion-gate01
Betaadrenergicblockers 150412052808-conversion-gate01Betaadrenergicblockers 150412052808-conversion-gate01
Betaadrenergicblockers 150412052808-conversion-gate01
 
Alphablockers 140105052831-phpapp02
Alphablockers 140105052831-phpapp02Alphablockers 140105052831-phpapp02
Alphablockers 140105052831-phpapp02
 
Anticholinergics drugs-Dr Ramesh Krishnan
Anticholinergics drugs-Dr Ramesh KrishnanAnticholinergics drugs-Dr Ramesh Krishnan
Anticholinergics drugs-Dr Ramesh Krishnan
 
6966901
69669016966901
6966901
 
Cholinergic ramesh
Cholinergic rameshCholinergic ramesh
Cholinergic ramesh
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
 
Pophyria
PophyriaPophyria
Pophyria
 
Porphyria r
Porphyria rPorphyria r
Porphyria r
 
Porphyria
PorphyriaPorphyria
Porphyria
 
Porphyria r (1)
Porphyria r (1)Porphyria r (1)
Porphyria r (1)
 
Shelly hyperlipidemia
Shelly hyperlipidemiaShelly hyperlipidemia
Shelly hyperlipidemia
 
Cvs 6
Cvs 6Cvs 6
Cvs 6
 
Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15
 

Niemann pick disease

  • 1. Niemann-Pick Disease Maggie W. George December 5, 2005
  • 2. The Disease  Condition involving the breakdown and use of fats and cholesterol in the body  Harmful amounts of lipids accumulate in the spleen, liver, lungs, bone marrow, and brain  Autosomal recessive pattern of inheritance (two copies of the gene must be present)  Four variants: A, B, C1, and C2  Clinical feature include: severe liver disease, breathing difficulties, developmental delay, seizures, increased muscle tone, lack of coordination, problems feeding, and inability to move eyes vertically.  No treatment
  • 3. Variants  Types A and B: mutated SMPD1 gene  SMPD gene carries instructions for cells to produce, sphingomyelinase, which processes lipids.  Mutations lead to deficiency of sphingomyelinase and accumulations of cholesterol and lipids.  Types C1 and C2: mutated NCP1 or NCP2 gene  NCP1 gene produces a protein involved in the movement of cholesterol and lipids within a cell.  May be a cholesterol pump, which is why its mutation leads to the buildup of lipids and cholesterol in the cell membrane.  Plays a critical role in regulation of intracellular cholesterol trafficking  NCP2 gene produces protein that binds and transports cholesterol (not fully understood).
  • 4. NCP1 v. NCP2 Gene  95% of patients have mutations in the NPC1 gene  Mapped at chromosome 18q11  NPC1 encodes a 1278 amino acid glycoprotein with 13 transmembrane domains.  Remainder of patients have mutations in the NPC2 gene (or HE1 gene)  Mapped at chromosome 14q24.3  Encodes a small soluble lysosomal protein involved in cholesterol binding.  Both genes have identical biochemical patterns suggesting that the two proteins function together in cellular transport of cholesterol, glycolipids, etc.  Work together to facilitate the intracellular transport of lipids from the lysosome to other cellular sites.  Their precise functions and relationship remain unclear and are currently the subject of intense investigation.
  • 5. NCP1 Mutations  Over 130 mutations have been identified in NPC1  Results in Niemann-Pick Disease Type C1  Most found within a NPC1 specific cysteine-rich domain, suggesting that the integrity of this region is crucial for normal functioning of the protein.  Mutations include: missense mutations, small deletions that generate premature stop codons, intronic mutations predicted to alter splicing, and point mutations. Specific mutation examples:  exon 20 c.2932 C>T  c.882-28 A>G (note that patients with this mutation had fibroblasts containing small amounts of mRNA without exon 7)  point mutation in exon 20 (causing frameshift and premature stop codon)  1553G-A transition (causing a splicing error of exon 9)  2783A-C transversion that results in a gln928-to-pro amino acid substitution  3263A-G transition leading to a tyr1088-to-cys amino acid substitution  530G-A change in exon 5, resulting in a cys177-to-tyr substitution  4-bp deletion, TTAC
  • 6. NCP2 Mutations  Results in Niemann-Pick Disease Type C2 and frontal lobe atrophy  Single amino acid changes prevents both cholesterol binding and the restoration of normal cholesterol levels in mutant cells. Specific mutation examples: 16 mutant alleles were identified representing only 5 different mutations (all had a severe impact on the protein): 1. 2 nonsense mutations, glu20 to ter (E20X): associated with severe rapid disease course • Results in a frameshift in exon 2, which generates a stop codon 4 codons downstream of frameshift • Lung involvement  death from respiratory failure 1. Glu118 to ter substitution (E118X) • Result of a G-to-T transversion at nucleotide 352 in exon 1 of HE1 gene 1. 1-bp deletion (27delG) 2. Splice mutation (IVS2+5G-A): very difference clinical presentation • Milder phenotype • Childhood onset of neurologic symptoms but prolonged survival 1. Missense mutation (S67P)  resulting in reduced amts of abnormal HE1 protein. *E20X was established as the most common mutant allele (56% frequency)
  • 7. Lack of Knowledge  Unfortunately, the NCP1 and the NCP2 gene are not fully understood, which means there is no proposed structure for either.  There is a structure for the NCP2 bovine gene, but then again there is little information about the actual mutations involved.
  • 8. Human to Bovine Relationship
  • 9.
  • 10.
  • 11. References  http://en.wikipedia.org/wiki/Niemann-Pick_disease  http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search  http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed  http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=PubMed&cmd=Retrieve&list_uids=12401890  http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=PubMed&cmd=Retrieve&list_uids=15774455  http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_u ids=12974729&query_hl=1&itool=pubmed_docsum